for people ages 18 years and up (full criteria)
study started
completion around
Principal Investigator
by Michael J Peluso, MD (ucsf)
Headshot of Michael J Peluso
Michael J Peluso



Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.

Official Title

An Exploratory, Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of an Anti-SARS-CoV-2 Monoclonal Antibody and Response to Treatment in Individuals With Long COVID (outSMART-LC)


The study will enroll approximately 30 participants who meet the World Health Organization (WHO) Long COVID criteria, with Long COVID attributed to a SARS-CoV-2 variant susceptible to AER002. Participants will be enrolled at a single center and randomized 2:1 to receive a SARS-CoV-2 monoclonal antibody (AER002) 1200mg or placebo. Evaluations will take place at baseline and at timepoints up to 1-year post-infusion.


Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19, COVID-19, Post-acute Sequelae of SARS-CoV-2 infection, Post-Acute COVID-19 Syndrome, AER002


You can join if…

Open to people ages 18 years and up

(note, additional eligibility criteria not listed here will be assessed at Screening):

- Male, female, or transgender ≥18 years of age at Screening. - History of confirmed acute SARS-CoV-2 infection. - Long COVID attributed to a SARS-CoV-2 infection with a variant against which AER002 is known to have neutralizing activity (prior to August 15, 2022). Note: While individuals re-infected with SARS-CoV-2 after August 15, 2022 will not be excluded, the SARS-CoV-2 infection after which Long COVID symptoms began must pre-date August 15, 2022. - At least two symptoms that are new or worsened since the time of SARS-CoV-2 infection, not known to be attributable to another cause upon assessment by the PI. Symptoms must have been present for at least 60 days prior to screening and must be reported to be at least somewhat bothersome. - Body mass index (BMI) 18 to 50 kilograms/meter squared (kg/m2), inclusive, at the time of screening. - Participants who are of childbearing potential (CBP) and male participants with sexual partner(s) who are females of CBP must agree to use adequate contraception from study consent through 360 days after dosing.

You CAN'T join if...

(note, additional eligibility criteria not listed here will be assessed at Screening):

- Long COVID attributed to a SARS-CoV-2 infection after August 15, 2022. - Previously received treatment or prophylaxis with a SARS-CoV-2-specific mAb, or plan to receive such treatment before exiting the study. - Previously received COVID-19 convalescent plasma treatment within 60 days prior to Day 0 or plan to receive such treatment before exiting the study. - Plans to receive any investigational or approved vaccine or booster for SARS-CoV-2 within 60 days prior to Day 0 or before Day 30 following Day 0. - Active cardiovascular disease or recent (within 3 months) stroke. - Recent (within 6 months) or planned major surgery. - Currently hospitalized or recent (within 1 month) unplanned hospitalization. - Active Hepatitis Bor C infection . - Untreated or unstable HIV infection (two or more consecutive plasma HIV RNA values >48 copies/mL in the 6 months prior to screen). - Severe coagulopathy (international normalized ratio ((INR) >2.0, history of hemophilia). - Severe anemia (hemoglobin <9 grams/deciliter (g/dL)). - Moderate or severe immunocompromise, according to the current NIH COVID-19 Treatment Guidelines as of March 6, 2023. - History of anaphylaxis or hypersensitivity upon receiving IV antibody infusions, any componenets of the intervention, prescription or non-prescription drugs, or food products in the past. - Pregnant, breastfeeding, or unwilling to practice birth control abide by the contraception requirements outlined in the inclusion criteria. - Participation in a clinical trial with receipt of an investigational product within 28 days or 5 half-lives (whichever is longer) prior to Day 0. - Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.


  • UCSF/Zuckerberg San Francisco General Hospital
    San Francisco California 94110 United States

Lead Scientist at University of California Health

  • Michael J Peluso, MD (ucsf)
    I am an infectious disease clinical-translational physician-scientist. My primary interests are HIV and COVID-19. I am involved with clinical and laboratory research aimed at understanding the HIV reservoir and implementing clinical trials to disrupt the reservoir with the aim of inducing antiretroviral therapy-free HIV remission.


in progress, not accepting new patients
Start Date
Completion Date
Michael Peluso, MD
Phase 2 COVID-19 Research Study
Study Type
Expecting 30 study participants
Last Updated